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Abstract
Introduction. The problem of heart rhythm disturbances is one of the most urgent topics of modern cardiology. Ac-
cording to the currently available concepts, 1,2- and 1,3-disubstituted aminoindole derivatives, which compound 
2-phenyl-1-(3-pyrrolidin-1-il-propyl)-1H-indole hydrochloride (SS-68) belongs to, are a promising chemical group in 
terms of their cardio-pharmacological activity.
Materials and methods. To study the anti-arrhythmic activity of SS-68 compound, the following models were used: 
1) Models of cardiogenic arrhythmia: aconitine-inducedic, calcium chloride-induced, barium chloride-induced, cesium 
chloride-induced, adrenaline model of arrhythmia, strophanthine-induced arrhythmias, as well as arrhythmias caused 
by electrostimulation and acute myocardial ischemia; 2) neurogenic arrhythmias: arrhythmias caused by administration 
of aconitine, strophanthine K, cesium chloride into the IV ventricle of the brain and also by applying carbachol on the 
somatosensory cortex. To assess the antianginal activity of SS-68 in various models, the effect of this drug and compar-
ators on the intact and ischemic myocardium was studied.
Results. It was found that with cardiogenic arrhythmias, SS-68 compound exhibits a pronounced antiarrhythmic effect 
and brings to normal the electrophysiological pattern of the heart, in most cases exceeding the analogous effect of ref-
erence drugs (amiodarone, lidocaine, aymaline, ethacizine, etmozine, quinidine anaprilin). In neurogenic arrhythmias, 
SS-68 also had a stopping effect, and, in addition, reduced the epileptiform activity of the brain in the model with the 
application of carbachol on the somatosensory cortex. In the study of antianginal and coronary vasolidating activities, 
SS-68 demonstrated pronounced thrombolytic and anti-ischemic activities, manifested in an increase in the coronary 
blood flow, a positive effect on ST-segment depression, and a decrease in the area of necrosis in experimental myocar-
dial infarction.
Discussion. The antiarrhythmic and antianginal activities of SS-68 compound create the prerequisites for further study 
of the pharmacological properties of this molecule. In addition, it seems appropriate to continue studying the pharma-
codynamics, pharmacokinetics and molecular mechanisms of SS-68 action.
Conclusions. SS-68 compound is a promising pharmacological agent with a high activity towards various electrophys-
iological disorders in the heart, and, in addition, it has significant antiischemic and coronary vasolidating properties.
Copyright Bogus SK et al. This is an open access article distributed under the terms of  the Creative Commons Attribution License (CC-BY 4.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Introduction
According to the World Health Organization, every year 
more than 17 million people die of cardiovascular disea-
ses and related complications, including heart rhythm 
disturbances (HRD), especially atrial fibrillation (AF) 
(Golitsyn 2008, Karpov and Sorokin 2012, Opii and 
Gersh 2010, Roger et al. 2011).
The prevalence of AF as the most common cause of 
disability and a decline in the quality of life in Russia is 
3.2 per 1000 people (2.8 and 3.6 in men and women, re-
spectively) (Serdechnaya et al. 2007). AF leads to a de-
crease in exercise tolerance, development of heart failure, 
and a 5 to 7-fold increase in the risk of occurrence (in 
4.2-7.2% of cases) of thromboembolic complications, 
in particular ischemic stroke (Bunin and Mikishanskaya 
2018). Mortality of patients with AF range from 2.9 to 
4.2% (Serdechnaya et al. 2009, Revishvili et al. 2015, Be-
lousov et al. 2017, Serdechnaya et al. 2007, Gladstone et 
al. 2009, Naccarelli et al. 2009). Most of the antifibrilla-
tory drugs used in cardiac practice have serious deficien-
cies, the main of which are narrow therapeutic windows 
(TW) and a number of cardiac and extracardiac side ef-
fects (Kryzhanovsky and Vititnova 2008, Galenko-Yaro-
shevsky et al. 2012a, 2012b, 2012f, DiMarco et al. 2010, 
Crea et al. 2011).
Solving the problems of treating patients with AF can 
be significantly promoted by new antifibrillatory drugs, 
more effective and less toxic than the existing ones 
(Galenko-Yaroshevsky and Gatsura 2009, 2011, Galen-
ko-Yaroshevsky et al. 2012а, Nesterenko et al. 2014). 
What is important is that the newly created antiarrhythmic 
drugs, along with their high activity, also have positive 
pleiotropic (multiple) properties (Galenko-Yaroshevsky 
and Gatsura 2009, Grigorieva 2010, Belenkov et al. 2011, 
Titenkov 2012, Zannad et al. 2011). The latter is due to 
the fact that multicomponent therapy is very important 
both for the treatment of patients with AF and for the pre-
vention of its complications (Revishvili et al. 2015, Zan-
nad et al. 2011).
According to the published data, indole derivatives 
can exhibit antiarrhythmic, antiischemic (antianginal), 
antihypertensive, antiaggregant, anti-sclerotic, anti-in-
flammatory, analgesic and other properties (Amelin et al. 
2010, Mashkovsky 2010, DiMarco et al. 2010, Crea et 
al. 2011).
Based on the foregoing, it seems reasonable to study the 
pharmacological activity of the new 1,2- and 1,3-disub-
stituted amino derivatives of indole, in particular 2-phe-
nyl-1-(3-pyrrolidin-1-il-propyl)-1H-indole hydrochloride 
(SS-68 compound).
Materials and methods
The experiments were carried out in accordance with the 
requirements of GOST ISO/IEC 1704-2009, GOST R ISO 
5725-2002 and The Rules of laboratory practice approved 
by Order № 708n of the Ministry of Health and Social De-
velopment of the Russian Federation on August 23, 2010, 
in compliance with The European Convention for the 
Protection of Vertebrates Used for Experiments or Other 
Scientific Purposes (Directive 2010/63/EU). The experi-
ments were conducted in accordance with The Guidelines 
for Pre-clinical Study of Medicinal Products (2012).
The aconitine-induced arrhythmia model was repro-
duced on nonlinear conscious and anesthetized (ethami-
nal-sodium 40-50 mg/kg intraperitoneally) male rats (Ga-
lenko-Yaroshevsky et al. 2012c).
Calcium chloride-induced arrhythmia model was 
used in experiments on conscious nonlinear rats (Galen-
ko-Yaroshevsky et al. 2012c).
Barium chloride-induced arrhythmia model was used 
on conscious rabbits (Galenko-Yaroshevsky et al. 2012d).
Cesium chloride-induced arrhythmia model was stud-
ied in experiments on anesthetized (urethane 1.0-1.3 g/
kg intraperitoneally) nonlinear male rats (Galenko-Yaro-
shevsky et al. 2012a, 2012d).
Adrenaline model of arrhythmia was used on anesthe-
tized rats by rapid intravenous injection of an adrenaline 
solution at a dose of 0.3 mg/kg (Mironov 2012).
Strophanthine-induced arrhythmia model was used 
on anesthetized cats (etaminal-sodium 50 mg/kg intraper-
itoneally) (Mironov 2012).
Ventricular HRDs (in the late stage of myocardial 
infarction (MI)) were induced in experiments in anesthe-
tized (ethaminal-sodium 40 mg/kg intrapleurally) dogs 
(Galenko-Yaroshevsky et al. 2012c).
The antifibrillatory activity of substances was stud-
ied in experiments on anesthetized cats (etaminal-so-
dium 40 mg/kg intraperitoneally) by determining the 
threshold of ventricular fibrillation (VF) of the heart 
(Hageman et al. 1986, Mironov 2012). VF was caused 
by the electrostimulator designed by (Storozhuk and 
Naumov 1981), which allows applying rectangular elec-
trical pulses starting from 2 mA, duration from 5 to 200 
ms in the sensitive period of the ECG, recorded in the 2nd 
standard lead. Defibrillation was performed with an ID-
66 defibrillator at a voltage of 2.5 to 3.5 kV. The current 
discharge was applied onto the chest of the animal. The 
experiments were performed on animals with intact and 
infarcted myocardium, while MI was induced by occlu-
sion of the left anterior descending artery (LAD) at the 
border of its upper and middle thirds.
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Early post-occlusion (EPOA) and reperfusion ar-
rhythmias (ERA) were caused in anesthetized (sodi-
um-ethanol 40 mg/kg intraperitoneally) cats according to 
the methods described in (Gendenshtein et al. 1990).
The influence of the substances on the effective re-
fractory period of the atria was studied in experiments 
on isolated atrial appendages of guinea pigs of both sexes 
according to the method described in (Senova 1963).
The influence on HRD induced by mechanical de-
struction of the sinus node and subsequent electro-
stimulation of the atria in dogs. The experiments were 
performed in anesthetized (pentobarbital-sodium 40 mg/
kg intravenously or 50 mg/kg intrapleurally) dogs of both 
sexes according to the method described in (PA Galen-
ko-Yaroshevsky et al. 2012d).
The influence on HRD induced by paired atrial stim-
ulation against vagal cardiac arrest initiated by tonic 
stimulation of the vagal nerve (VN). The experiments 
were performed in anesthetized (1% mixture of α-chlo-
ralose and ethaminal-sodium 75 and 15 mg/kg, respec-
tively) cats using the method of (Sheikh-Zade et al. 1985).
The influence on the dynamics of the excitation fo-
cus in the sino-atrial node (SAN) during VN stimulation 
was studied in experiments in anesthetized (urethane 1.2 
g/kg intraperitoneally) cats according to the method de-
scribed in (Somov and Pokrovsky 2014).
The influence on the pool dynamics on pools of the 
initial excitation source in SAN in kittens with idiopath-
ic sick sinus syndrome was studied in anesthetized (ure-
thane 1.2 g/kg intraperitoneally) kittens according to the 
method described in (Somov and Pokrovsky 2014).
A study of the influence of the test substances on ar-
rhythmias induced by administering aconitin, strophan-
thine K and cesium chloride into the IV ventricle of the 
brain was performed in anesthetized (40 mg/kg of α-chlo-
ralose and 30 mg/kg of ethaminal-sodium intraperitoneal-
ly) cats (Galenko-Yaroshevsky et al. 2012c).
The influence on the bioelectrical activity of somatosen-
sory cortex (SSC) and HRD induced by microapplication of 
carbachol (CCh) on cortical structures of the brain was in-
vestigated in experiments in white nonlinear rats of both sex-
es according to the method described in (Sukhov et al. 2011).
The influence on the coronary artery flow velocity 
(CAFV) was studied in anesthetized (ethaminal-sodium 
40-50 mg/kg intraperitoneally) cats of both sexes by the 
method by (Moravitz and Zahn 1912) in the modification 
of Kaverina (1958). At the same time, blood pressure in the 
carotid artery and heart rate were recorded. Myocardial ox-
ygen demand (MOD) was calculated by the rate pressure 
product method (RPP), which is a BP × heart rate × 10-3.
The influence of intracoronary injection of SS-68 
compound on the phasic coronary blood flow (PCBF) 
was studied in experiments in dogs; systemic arterial 
blood pressure, reactive hyperemia (RH) lasting 20 sec 
(Khomazyuk 1985), left ventricular pressure (LVP), the 
rate of its changes (dP/dt+and dP/dt-) and heart rate (HR) 
were recorded (Sheikh-Zade 1985, Konstantinov et al. 
1986, Orlov et al. 1987).
The influence on myocardial contractility and the phase 
structure of the cardiac cycle (PSCC) was studied in ex-
periments in anesthetized (ethaminal-sodium 40 mg/kg in-
traperitoneally) cats according to (Sheikh-Zade 1985). The 
durations of the cardiac cycle (DCC), of the phases of asyn-
chronous (DPAC) and isometric contraction (DPIC), of the 
periods of tension DPT) and ejection (DPE), of the systole 
(DS), of the diastole (DD) and of P-Q and Q-T ECG intervals 
were determined, as well as LVP, the maximum discharge 
rate/temperature drop in the left ventricle (dP/dt+). Evalua-
tion of the phase structure of the cardiac cycle and myocardi-
al contractility was performed according to the ADM.
The influence on the main indicators of heart activi-
ty and hemodynamics was investigated in experiments on 
rats and cats. After fixing the anesthetized (urethane 1.3 g/
kg intraperitoneally) white non-linear male rats on the op-
erating table, the left femoral artery was catheterized to 
measure systemic blood pressure. Through the left com-
mon carotid artery, an ultrasonic sensor was inserted into 
the cavity of the left ventricle of the heart. The right femoral 
vein was catheterized for introducing the test compound. 
Simultaneously, ECG was recorded in the II standard lead. 
Based on the analysis of the recorded values, the following 
indicators of hemodynamics and heart activity were calcu-
lated according to the methods described in (Galenko-Yaro-
shevsky and Gatsura 2005): mean systolic blood pressure 
(SBP); heart rate; stroke volume of blood (SV); minute 
blood volume (MV); total peripheral resistance (TPR); and 
myocardial contractility (dP/dt). When studying cardiac ac-
tivity and general hemodynamics in experiments in narco-
tized (ethaminal-sodium 40 mg/kg intraperitoneally) cats, 
the thermodilution method was used. At the same time, MV 
and SV, cardiac output (Qc), cardiac (CI) and systolic pres-
sure indices (SPI), left ventricle work index (LVWI) and 
left ventricle stroke index (LVSI), TPR, BP and heart rate 
were selected as indicators of cardiohemodynamics.
The influence on CAFV, mean BP, MV and SV, con-
tractility (dP/dt+and dP/dt-) of the myocardium, heart 
rate were examined under conditions of ischemic (by oc-
clusion of the anterior interventricular branch of the left 
coronary artery – LAD on the border of the middle and 
lower third) of the myocardium in anesthetized (ethami-
nal-sodium 50 mg/kg intrapleurally) dogs, using an RM-
600 recorder by Nihon Kohden.
The collateral circulation (CC) was examined by 
means of recording the volume velocity of the retrograde 
blood flow (VVRF) ligated in the distal part of the LAD in 
anesthetized dogs (ethaminal-sodium 50 mg/kg intraperi-
toneally) (Gatsura and Bandurina 1964). The ability of the 
substance to cause a redistribution of blood flow to the area 
of the ischemic site was estimated by the blood redistri-
bution rate (BRR), which is the ratio of VVRF to BP, ex-
pressed as a percentage (Saratikov et al. 1980). Along with 
the study of collateral circulation, changes in heart rate and 
MOD were studied. The latter indicator was calculated by 
the DP method (Galenko-Yaroshevsky et al. 2012c). Based 
on the DP, the myocardial CC was determined, which is 
the ratio of VVRF to DP, expressed as a percentage.
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The influence on coronary circulation under condi-
tions of myocardial ischemia induced by pituitrin was 
studied in experiments in anesthetized cats (ethaminal-so-
dium 40 mg/kg intraperitoneally). Spasm of the coronary 
vessels was caused by intravenous injection of pituitrin (5 
units/kg) (Mironov 2012).
The cardioprotective effect was studied in experiments 
in anesthetized (chloral hydrate 300 mg/kg) chinchilla 
breed rabbits. MI in animals on controlled respiration was 
caused by ligating LAD at the level of the lower edge of 
the left atrial appendage. Thirty minutes before the liga-
tion of the coronary artery, SS-68 at a dose of 2 mg/kg 
was injected into a rabbit’s marginal ear vein. Mildronate 
(Grindeks, Latvia) at a dose of 80 mg/kg was also ad-
ministered intravenously 30 minutes beforehands. Simi-
larly, 30 minutes before ischemia, a 5-minute episode of 
ischemic preconditioning was performed. Thirty minutes 
after coronary occlusion, the ligature was removed and 
myocardial reperfusion was performed for 90 minutes, 
after which blood was drawn from the right ventricle into 
a disposable vacuum tube with an anticoagulant to deter-
mine a specific marker of the cardiac muscle, troponin I. 
The level of troponin was determined on an immunoreflu-
orescence device Triage MeterPro (Biosite, USA), using 
the Cardiac Panel test system.
The evaluation of the area of necrotic myocardium 
was performed after the 1.5-hour reperfusion. Transverse 
sections of the myocardium were cut at each 0.8-cm in-
terval, starting from the level of 0.8 cm below the site of 
the ligature. Sections of the myocardium were placed in a 
container with phosphate buffer (pH=7.4) and 1 mg/ml of 
triphenyltetrazolium chloride for forming red formazan. 
The areas of the intact and necrotic left ventricular myo-
cardium were calculated on each of the 4 slices by means 
of pixel analysis via Adobe Photoshop 9.0.
The functional state of the ischemic focus of the 
myocardium was studied in experiments in anesthetized 
cats (ethaminal-sodium 40 mg/kg intraperitoneally), with 
ischemia modeled by occlusion (5 min) LAD in the mid-
dle third (Goldsteine 1984).
The antianginal activity of the substances was evalu-
ated by the depression of the total amount of the ST seg-
ment of the epicardial electrogram recorded from 6 points 
on the heart surface. The significant results were those in 
which the ST segment depression was higher than 10% 
(Galenko-Yaroshevsky et al. 2012e).
Experimental MI was modeled in the anesthetized cats 
(ethaminal-sodium 40 mg/kg intraperitoneally) by occlu-
sion of left anterior descending artery (LAD) at the border 
of the its upper and middle thirds, the size of the necrotic 
zone (NZ) was studied according to the method described 
in (Gatsura 1986).
Results
Depending on the selected models of arrhythmia, SS-68 
compound and reference drugs for antiarrhythmic activity 
can be represented in the following lines:
In aconitine-induced arrhythmia in conscious rats – 
amiodarone>SS-68 compound = lidocaine (Fig.1);
In aconitine-induced arrhythmia in anesthetized rats – 
amiodarone>SS-68 compound = lidocaine (Fig. 2);
Figure 1. Comparative activity [according to ED50 in mg/kg 
(shaded bars) and mM/kg (dark bars)], relative activity (RA), 
acute toxicity (LD50) and therapeutic window (TW) SS-68, 
amiodarone (Am) and lidocaine (Li) in the prevention of aconi-
tine-induced arrhythmia in experiments in conscious rats. Note: 
here and henceforward ED50 – effective dose; LD50 – dose that 
causes the death of 50% of animals; RA – relative activity; TW – 
therapeutic window
Figure 2. Comparative activity [according to ED50 in mg/kg 
(shaded bars) and mM/kg (dark bars)], relative activity (RA), 
acute toxicity (LD50) and therapeutic window (TW) of SS-68, 
quinidine (Qu), Aymalin (Ay), amiodarone (Am), and lidocaine 
(Li) used to arrest aconitine-induced arrhythmia in experiments 
in anesthetized rats. Note: ED50 – effective dose; LD50 – dose 
that causes the death of 50% of animals; RA – relative activity; 
TW – therapeutic window
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In calcium chloride-induced arrhythmia (rats) – ver-
apamil>SS-68 compound>amiodarone (Fig. 3);
The conducted experiments showed that SS-68 com-
pound can not prevent heart rhythm disturbances caused 
by calcium chloride, but only reduces the mortality of 
animals. Proceeding from this property of SS-68 com-
pound, the antiarrhythmic action of this compound and 
the reference drugs were evaluated by the survival rate 
of the animals.
It was established that SS-68 compound, when ED50 
is expressed in mg/kg, by its antiarrhythmic activity ex-
ceeds lidocaine and amiodarone 1.5 or over 2.6 times (at 
a dose of 15 mg/kg, antiarrhythmic effect was observed 
in 2 animals out of 10, which did not allow determining 
ED50), but was 4.8 times worse than verapamil. When 
ED50 is expressed in mM/kg, SS-68 compound in this re-
spect exceeds lidocaine and amiodarone 1.8 and over 1.3 
times, and is 7.0 times more than verapamil. By TW, SS-
68 compound exceeds lidocaine 2.9 times, but is 1.4 and 
2.0 times worse than verapamil and amiodarone (conven-
tionally) (Fig. 3);
In barium chloride-induced arrhythmia (rabbits) – SS-
68 compound>quinidine> amiodarone (Fig. 4);
It was established that SS-68 compound – with ED50 
expressed in mg/kg and mM/kg – shows a very pronoun-
ced antiarrhythmic effect. So, by this effect, this substance 
exceeds amiodarone and quinidine 50.0 and 84.4, 22.0 and 
32.3 times, respectively. By TW, SS-68 compound ex-
ceeds amiodarone and quinidine 1.6 and 8.4 times (Fig. 4);
In cesium chloride-induced arrhythmia (prophylactic 
action) in rats – SS-68 compound> amiodarone (Fig. 5);
Figure 3. Comparative activity [by ED50 in mg/kg (shaded bars) 
and mM/kg (dark bars)], relative activity (RA), acute toxicity 
(LD50) and therapeutic window (TW) of SS-68, amiodarone 
(Am), lidocaine (Li), and verapamil (Ve) used to prevent cal-
cium chloride-induced arrhythmia in experiments in conscious 
rats. Note: ED50 – effective dose; LD50 – dose that causes the 
death of 50% of animals; RA – relative activity; TW – thera-
peutic window
Figure 4. Comparative activity [according to ED50 in mg/kg 
(shaded bars) and mM/kg (dark bars)], relative activity (RA), 
acute toxicity (LD50) and therapeutic window (TW) of SS-68, 
quinidine (Qu) and amiodarone (Am) used to arrest barium 
chloride-induced arrhythmia in experiments in conscious rab-
bits. Note: ED50 – effective dose; LD50 – dose that causes the 
death of 50% of animals; RA – relative activity; TW – thera-
peutic window
Figure 5. Comparative activity [according to ED50 in mg/kg 
(shaded bars) and mM/kg (dark bars)], relative activity (RA), 
acute toxicity (LD50) and therapeutic window (TW) of SS-68 
and amiodarone (Am) used to prevent chloride cesium arrhyth-
mia in experiments in anesthetized rats. Note: ED50 – effective 
dose; LD50 – dose that causes the death of 50% of animals; RA 
– relative activity; TW – therapeutic window
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In cesium chloride-induced arrhythmia (arrest) in rats 
–. SS-68 compound>amiodarone (Fig. 6)
In adrenaline-induced arrhythmia (rats) – anaprilin>a-
tenolol>SS-68 compound> amiodarone (Fig. 7);
In strophanthine-induced arrhythmia (cat) – verapa-
mil>aymalin>SS-68 compound> quinidine>lidocaine 
(Fig. 8);
SS-68 compound demonstrated the most significant 
activity in conditions of barium chloride-induced arrhy-
thmia, which is specific for class III antiarrhythmics (bloc-
kers of K+-channels), in this respect exceeding amiodaro-
ne and quinidine 50 and 85 times, respectively (Fig. 4);
Antiarrhythmic activity in ventricular arrhythmias
The influence on heart rhythm disturbances caused by a 
two-stage coronary artery ligation in anesthetized dogs.
The conducted studies showed that for SS-68 compound 
the threshold anti-arrhythmic dose (TAD), which termi-
nates ventricular tachycardia and extrasystole under the 
accepted experimental conditions, is 2.8±0.4 mg/kg, 
whereas for lidocaine it is 7.2±0.9 mg/kg, i.e., TAD of 
the former is 2.6 times less (p<0.01) than that of the latter 
(Fig. 9). It is important to note that for SS-68 compound 
the highest TAD is 4 mg/kg, and for lidocaine – 8 mg/kg, 
respectively, which makes up 7.5 and 28.6% of their LD50 
(with intravenous administration to rats).
SS-68 compound and lidocaine by their ability to 
maximally reduce the number of ectopic ventricular 
contractions (EVC) (4.0±1.9% vs. 1.8±0.9%, p> 0.05), 
Figure 6. Comparative activity [according to ED50 in mg/kg 
(shaded bars) and mM/kg (dark bars)], relative activity (RA), 
acute toxicity (LD50) and therapeutic window (TW) of SS-68 
and amiodarone (Am) used to treat cesium chloride-induced ar-
rhythmia in experiments in anesthetized rats. Note: ED50 – effec-
tive dose; LD50 – dose that causes the death of 50% of animals; 
RA – relative activity; TW – therapeutic window
Figure 7. Comparative activity [according to ED50 in mg/kg 
(shaded bars) and mM/kg (dark bars)], relative activity (RA), 
acute toxicity (LD50) and therapeutic window (TW) of SS-68, 
amiodarone (Am), atenolol (At), and anaprilin (An) used to pre-
vent adrenal-induced arrhythmia in experiments in anesthetized 
rats. Note: ED50 – effective dose; LD50 – dose that causes the 
death of 50% of animals; RA – relative activity; TW – thera-
peutic window
Figure 8. Comparative activity [according to ED50 in mg/kg 
(shaded bars) and mM/kg (dark bars)], relative activity (RA), 
acute toxicity (LD50) and therapeutic window (TW) of SS-68, 
quinidine (Qu), aymalin (Ay), lidocaine (Li), and verapamil (Ve) 
used to arrest strophanthine-induced arrhythmia in experiments 
in anesthetized cats. Note: ED50 – effective dose; LD50 – dose 
that causes the death of 50% of animals; RA – relative activity; 
TW – therapeutic window
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the maximal antiarrhythmic effect (MAE) (2.6±0.2 min 
vs. 2.0±0.4 min, p> 0.05) and the decrease time of an-
tiarrhythmic effect by 50% – DAE50 (10.0±2.1 min vs. 
9.0±2.1 min, p> 0.05) were almost comparable (Fig. 
9). Under the influence of SS-68 compound (122.6±4.4 
bpm vs. 139.2±6.7 at the end, by 88.4%, p>0.05) and 
lidocaine (135.0±10.5 bpm vs. 148.8± 10.3 bpm at the 
end, by 90.7%; p>0.05), the heart rate tends to decre-
ase (Fig. 9). When using SS-68 compound (4 mg kg, 
1% solution) and lidocaine (8 mg/kg, 1% solution) in 
their maximum TADs, it was found out that 1, 3, 5 and 
10 minutes after its intravenous administration, SS-68 
compound exerted the most significant antiarrhythmic 
effect: the amount of EVC is 1.8±0.9, 1.2±0.6, 0.6±0.2 
and 1.2±0.6%, respectively, against 74.2±7.7% at the 
end (in all cases p<0.001). In the subsequent time inter-
vals – at the 15th (10.2±3.9%, p<0.001), 20th (15.6±3.5, 
p<0.001), 30th (25.3±4.3%, p<0.01), 40th (36.4±5.2%, 
p<0.001) and the 50th minutes (52.8±4.9%, p<0.05) – 
antiarrhythmic effect of SS-68 compound gradually de-
creased, remaining statistically reliable; at the 60th mi-
nute, the number of EVC is comparable to such number 
of the background. The heart rate decreased somewhat 
(a trend within 50-60 min) (Fig. 9).
Thus, SS-68 compound in conditions of ventricular ar-
rhythmia caused by a two-stage coronary artery litigation 
in dogs has antiarrhythmic effect, considerably exceeding 
lidocaine in this respect. Both SS-68 compound and lido-
caine tend to reduce the heart rate.
Antifibrillatory activity in conditions of intact and in-
farcted myocardium in cats
As a result of the experiments, it was established that 
SS-68 compound at a dose of 5 mg/kg (1% solution, intra-
venously) in the conditions of the intact myocardium, by 
the ability to increase the ventricular fibrillation threshold 
(VFT), exceeds amiodarone at a dose of 10 mg/kg (1% 
solution, intravenously) 1.4 times, however, it is 1.2 times 
worse to it by the duration of action (Fig. 10).
With MI caused by occlusion of LAD, SS-68, as in the 
previous series of experiments, is 1.4 times more effective 
in its antifibrillatory activity than amiodarone. As for the 
duration of action, SS-68 is somewhat (1.2 times) superi-
or to amiodarone, but these differences were statistically 
unreliable (Fig. 10). Thus, SS-68 compound in experi-
ments with cats in conditions of the intact myocardium by 
its antifibrillatory activity is superior to amiodarone, and 
is inferior to it by the duration of action. 
The effect on early post-occlusive and reperfusion arrhy-
thmias in cats
It was found that in the control group of animals, early 
occlusive arrhythmias (EOA) did not occur in 58.3% of 
cases, and early reperfusion arrhythmias (ERA) occurred 
in 100% of cats, while in 75.0% of cases ventricular fibril-
lation (VF) occurs (Fig.11).
SS-68 compound at a dose of 2 mg/kg did not have a 
preventive effect with respect to EOA, ERA and VF. Use 
of SS-68 at a dose of 5 mg/kg prevented EOA in 50.0% of 
cases; ERA and VF did not occur in 100.0 and 83.3% of 
animals, respectively (Fig. 11).
Thus, SS-68 at a dose of 2 mg/kg has no significant 
effect on EOA and ERA, including VF, and at a dose 
of 5 mg/kg exhibits significant antiarrhythmic and an-
tifibrillatory effects, exceeding lidocaine (7 mg/kg) in 
this respect and is almost comparable to amiodarone 
(10 mg/kg).
Figure 9. Comparative activity (according to TAD) of SS-68 
and lidocaine (Li) in ventricular arrhythmias caused by a two-
stage coronary artery litigation in dogs. Note: TAD – threshold 
antiarrhythmic dose, EVC – ectopic ventricular contractions, 
MAE – maximum antiarrhythmic effect, DAE50 – decrease in 
antiarrhythmic effect by 50%, BPM – beats per minute (heart 
rate). * – the differences are statistically significant at p<0.01 
compared with lidocaine.
Figure 10. Comparative antifibrillatory activity (A) and dura-
tion of action (B) of SS-68 (5 mg/kg) and amiodarone (Am; 10 
mg/kg) under conditions of intact (IntM) and infarcted myocar-
dium (InfM) in cats. Note: IVFT – increased ventricular fibrilla-
tion threshold, DAE – duration of antifibrillatory effect.
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Antiarrhythmic activity in models of atrial cardiac 
rhythm disturbances
The influence on the effective refractory period of the iso-
lated atrial appendages of a guinea pig
As a result of the conducted studies, it was established 
that SS-68 caused an increase in the effective refractory 
period of the isolated atrial appendage. When compared 
with the known antiarrhythmic drugs, it turned out that 
SS-68 exceeded amiodarone, lidocaine and quinidine 2.8, 
2.5 and 10.4 times, respectively, but was 1.7 times inferior 
to ethacizine (Tab. 1, Fig. 12).
The influence on atrial flutter induced by mechanical de-
struction of the sinus node and subsequent electrostimu-
lation of the atria in dogs
The conducted studies showed that SS-68, at doses for 
antiarrhythmic activity (to arrest atrial flutter) expressed 
in mg/kg and mM/kg, exceeds quinidine, etmozine and 
amiodarone 12.4 and 5.4, 4.9, and 3.7, 5.1 and 2.5 times, 
respectively (Tab. 2, Fig. 13).
With atrial flutter along the mechanical destruction of 
the sinus node and subsequent electrostimulation of the 
atria in dogs, SS-68 by the antiarrhythmic activity ex-
ceeds etmosin and amiodarone almost in the same way, 
and quinidine – to a greater extent.
Figure 11. Comparative activity of SS-68 (5 mg/kg), lidocaine 
(L; 7 mg/kg) and amiodarone (A; 10 mg/kg) in early occlu-
sive (EOA) and reperfusion arrhythmias (ERA) in cats. Note: 
C – control, HRD – heart rhythm disturbance, VF – ventricular 
fibrillation of the heart. The figures in the light part of the bar 
charts are the number of animals without either arrhythmia or 
VF, in the dark part – the number of animals with arrhythmia 
and VF. * – the differences are statistically significant (p<0.05) 
compared with the control
Table 1. Antiarrhythmic Effect of comp. SS-68 Expressed in 
Effective Concentration (EC15), in Comparison with Some Anti-
arrhythmic Drugs, and in Relative Units, Where Amiodarone is 
Taken as the Reference Preparation.
Substance
Antiarrhythmic effect
EC151 (М/l) and confidence 
limits at р = 0.05
in relation to 
amiodarone
SS-68 4.10 ×10
-7
2.92 × 10-7 ÷ 5.28 × 10-7 2.8
Ethacizine2 2.40 × 10
-7
1.70 × 10-7 ÷3.10 × 10-7 4.8
Quinidine3 4.26 × 10
-6
4.11 × 10-6 ÷ 4.39× 10-6 0.27
Lidocaine 1,02 × 10
-6
0.84 × 10-6 ÷ 1.20 × 10-6 1.1
Amiodarone 1.15 × 10
-6
0.84 × 10-6 ÷ 1.46 × 10-6 1.0
Note: 1EC15 – effective concentration of the substance, increas-
ing the refractory period by 15%; 
2 – Tikhonova 1990; 
3 – Sirotenko 2003.
Table 2. Antiarrhythmic Effect of SS-68, Quinidine, Etmozine 
and Amiodarone When Administered Intravenously by the 
Method of Biological Titration in Conditions of Atrial Flutter 
in Dogs.
Substance
Dose to arrest atrial flutter Antiarrhythmic 
effect in relation to 
amiodaronemg/kg мМ/kg
SS-68 1.86±0.24* 0.0055 5.05/2.51
Quinidine 23.0±1.252 0.0296 0.41/0.47
Etmozine 9.2±1.672 0.0204 1.02/0.68
Amiodarone 9.4±0.6 0.0138 1.0/1.0
Note: * – p<0.001 relative to all the reference drugs. 
1 – in the numerator – relative to the dose of amiodarone, ex-
pressed in mg/kg, in the denominator – in mM/kg; 
2 – Senova 1973;
3 – Dolskaya 2010.
Figure 12. Comparative activity (according to EC15) of SS-68, 
ethacizine, quinidine, lidocaine and amiodarone in their effect 
on the effective refractory period of the isolated atrial append-
age of a guinea pig. Note: EC15 – effective concentration of the 
substance, increasing the refractory period by 15%.
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The influence on fibrillation of atria induced by their pai-
red stimulation on the background of vagal heart failure 
initiated by tonic stimulation of the vagus nerve in cats
SS-68 at a dose of 20 μg/kg 5, 30, 60 and 120 min after 
intravenous administration caused a significant decrease 
in the duration of atrial fibrillation (AF) by 54, 38, 35 and 
33%, respectively. Along with this, the tonic component 
of the chronotropic effect of the vagus nerve (VN) decre-
ased by 38, 29, 15 and 20%, respectively.
As for the P-P and P-Q ECG intervals, the atrial excita-
tion threshold, the effective refractory period, the sinoatrial 
conduction of excitation, the VN stimulation threshold and 
the synchronizing component of the chronotropic effect of 
VN, they did not undergo significant changes (Tab. 3).
At a dose of 50 μg/kg 5, 30, 60 and 120 min after intra-
venous administration, SS-68 compound induced a signi-
ficant decrease in the duration of AF by 85%, 73%, 50% 
and 33%, respectively.
SS-68 exerted a vagolytic effect, which was evident in 
a significant increase in the stimulation threshold of VN 
by 16% (by the 5th minute of the study), synchronizing 
and tonic components of the chronotropic effect of VN 
by 50% and 47%, 41% and 41%, 41% and 37%, 37% and 
31%, respectively (by the 5th, 30th, 60th and 120th minutes 
of the study) (Tab. 3).
It should be noted that in 2 experiments out of 8, SS-68 
did not cause the synchronizing component of the chro-
notropic effect of VN when compared to the baseline. 
With increasing the dose, of SS-68 to 250 μg/kg, after 5, 
30, 60 and 120 min, a statistically significant decrease in 
the duration of AF was recorded – by 92%, 84%, 62% 
and 54%, respectively. The R-P and P-Q ECG intervals, 
as well as the effective refractory period, significantly in-
creased: the first indicator – by 13%, 10% and 8% (by 
the 5th, 30th and 60th min), the second – by 22% and 14% 
(by the 5th and 30th min), the third – by 18%, 13% and 
12% (by the 5th, 30th and 60th minutes of the study). The 
atrial excitation threshold and the sinoatrial conduction 
of excitation were virtually unchanged. Vagolitic activity 
of SS-68 compound clearly manifested itself in a signi-
ficant increase in the threshold for stimulation of VN by 
24% and 14% (by the 5th and 30th minutes) and inhibition 
of the synchronizing and tonic components of the chro-
notropic effect of this nerve by 62% and 58%, 60% and 
52%, 58% and 44%, 56% and 42%, respectively (by the 
5th, 30th, 60th and 120th minutes of the study) (Tab. 3). Ni-
feridil, used as a reference drug, at a dose of 10 μg/kg 5, 
30, 60 and 120 min after its intravenous administration 
caused a significant decrease in the duration of AF, which 
was 46%, 27%, 23% and 22%, respectively. In addition, 
there was a decrease in both the tonic and synchronizing 
components of the chronotropic effect of VN, while the 
P-P and P-Q ECG intervals, the atrial excitation thres-
hold, the sinoatrial conduction of excitation and the VN 
stimulation threshold remained virtually unchanged from 
the baseline data. Thus, SS-68 compound in conditions of 
neurogenic AF, caused by stimulation of VN in cats, has a 
dose-dependent antiarrhythmic effect. SS-68 at a minimal 
antiarrhythmic dose (20 μg/kg), unlike niferidil (10 μg/
kg), does not have a significant effect on the synchroni-
zing component of the chronotropic effect of VN. By its 
antifibrillatory effect, SS-68 is inferior to niferidil.
The influence of SS-68 on the dynamics of the excitation 
foci (EF) in the sinoatrial node when stimulating the va-
gal nerve in cats
In anesthetized cats with an open thorax and pericardi-
um, on controlled respiration, the initial heart rate was 
172.3±1.2 bpm. In a high-frequency electric field, one EF 
with an area of 0.04±0.003 mm2, localized at the opening 
Figure 13. Comparative activity of SS-68, quinidine (Qu), et-
mozine (Et) and amiodarone (Am) in dogs with atrial flutter. 
Note: bar charts: shaded bars – doses in mg/kg, dark bars – dos-
es in mM/kg; figures above the bars: in the numerator – doses in 
mg/kg, in the denominator – doses in mM/kg. The data charac-
terizing quinidine and etmozine are given according to (Senova 
et al. 1973), amiodarone – according to (Dolskaya 2010).
Table 3. Influence of SS-68 at Doses of 20, 50, 250 μg/kg on the Duration of Atrial Fibrillation Before and 5, 30, 60 and 120 Minutes 
After Administration of the drug (Reference Drug – Nifedipine at a Dose of 10 μg/kg).
Substance Baseline
The duration of atrial fibrillation (% of the baseline)
5 min after drug 
administration
30 min after drug 
administration
60 min after drug 
administration
120 min after drug 
administration
SS-68 (20 μg/kg i/v) 208.0±26.0 95.0±19.0* (46.0%) 129.0±27.0* (62.0%) 136.0±26.0* (65.0%) 140.0±27.0* (67.0%)
SS-68 (50 μg/kg i/v) 140.0±7.0 21.0±4.0* (15.0%) 38.0 ± 6.0* (27.0%) 70.0 ± 12.0* (50.0%) 94.0 ± 14.0* (67.0%)
SS-68 (250 μg/kg i/v) 150.0±8.0 12.0±4.0* (8.0%) 24.0±5.0* (16.0%) 58.0±6.0* (38.0%) 70.0±6.0* (46.0%)
Niferidil (10 μg/kg i/v) 102.0±12.0 55.0±8.0* (54.0) 74.0±12.0* (73.0) 79.0±14.0* (77.0) 80.0±12.0* (78.0)
Note: * – the differences are statistically significant (p<0.05) compared to the baseline.
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of the cranial vein, was visible. Under the microscope, the 
EF was not homogeneous and was like luminous pools 
(Tab. 4, Fig. 14).
The influence of SS-68 compound on cardiac rhythm dis-
turbances of neurogenic origin
Antiarrhythmic activity in conditions of cardiac rhythm 
disturbances induced by injecting aconitine into the IV 
ventricle of the cat’s brain
It was established that SS-68 compound, when used to 
arrest aconitine-induced arrhythmia of the central origin 
in experiments on cats, by its antiarrhythmic activity with 
ED50 expressed in mg/kg is more superior than amio-
darone, etmozine, ethacizine and lidocaine, is inferior to 
anaprilin, and with ED50 expressed in mM/kg, it is more 
superior than amiodarone, lidocaine and etmozine and 
practically does not differ from anaprilin and ehtacizine. 
By TW, SS-68 is more significant than all the reference 
drugs (Fig. 16).
Antiarrhythmic activity in conditions of cardiac arrhy-
thmias induced by injecting strophanthine K in the IV 
ventricle of the cat’s brain
SS-68 compound, when used to arrest strophanthine-in-
duced arrhythmia of central origin in experiments on cats, 
by antiarrhythmic activity is more significant than amio-
darone, etmozine and lidocaine, is inferior to verapamil, 
anaprilin and ethacizine. By TW, SS-68 is more signifi-
cant than anaprilin, ethacizine, etmozine and lidocaine, 
but is inferior to amiodarone and verapamil (Fig. 17).
Table 4. Effect of SS-68 on the Dynamics of the Excitation Foci 
in the Sinoatrial Node when stimulating the vagus nerve in cats
Parameters Initial Bradicardia
After 
injection of 
SS-68
Heart rate 172.3±1.2 140.4±1.8
р1 = 0.01
164.7±1.2
р2 = 0.01
р3 = 0.01
EF area, mm2 0.040±0.003 0.042±0.002
р1 > 0.05
0.042±0.004
р2 > 0.05
р3 > 0.05
Vertical localization of 
the EF from the opening 
of the cava, mm
3.2±0.3 5.7±0.4
р1 = 0.01
4.3±0.1
р2 = 0.01
р3 = 0.01
Horizontal localization of 
the EF from the edge of 
the cava, mm
1,0±0,2 1,8±0,1
р1 = 0,01
1,0±0,2
р2 > 0,05
р3 = 0,01
In-depth localization of 
the EF from the edge of 
the node, mm
0.43±0.02 0.46±0.01
р1 > 0.05
0.44±0.01
р2 > 0.05
р3 > 0.05
EF brightness histogram, 
bit 150.0±1.4
108±1.0
р1= 0.01
148.0±1.2
р2 = 0.01
р3 = 0.01
Minimum wavelength 
limit, nm 410±2,8
468±3,4
р1 = 0,01
465,0±4,5
р2 = 0,01
р3 > 0,05
Maximum wavelength 
limit, nm 642.7±4.1
568±4.2
р1 = 0.01
610.0±3.8
р2 = 0.01
р3 = 0.01
Range, nm 232.7±3.2 100.0±1.5
р1 = 0.01
145.7±1.8
р2 = 0.01
р3 = 0.01
Wavelength median, nm 550.4±2.7 475.2±2.2
р1= 0.01
480.0±3.0
р2 = 0.01
р3 = 0.01
Note: p1 – reliability factor between the data of columns 1 and 2: 
p2 – reliability factor between the data of columns 1 and 3; p3 – 
reliability factor between the data of columns 2 and 3
Figure 14. Influence of SS-68 on the EF (in blue) in the cat’s 
SAN. Note: a – the initial state, b – with stimulating VN, c –45 
minutes after the administration of SS-68; g – in 45 minutes with 
vagal-cardiac synchronization (VCS).
Figure 15. EF migration (blue against black background) of 
SAN in a cat. Note: A – the localization scheme for the cat’s 
SAN. B – localization of the EF in the SAN: a – the initial EF 
localization; b – EF localization in case of bradycardia caused 
by stimulatng VN with electrical pulses in a batch mode; c – lo-
calization of the EF 45 minutes after the administration of SS-
68. C – the morphological structure of the SAN (left) and the 
localization of the EF in the depth of the SAN (right).
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Antiarrhythmic activity in conditions of cardiac arrhy-
thmias induced by injecting cesium chloride in the IV 
ventricle of the cat’s brain
It was established that SS-68 compound, in conditions of 
cesium chloride- induced arrhythmia of the central origin 
in experiments in anesthetized cats, by its antiarrhythmic 
activity is more significant than amiodarone, and by TW, 
it is inferior to it (Fig.18).
The influence of SS-68 compound on the bioelectrical 
activity of the somatosensory cortex and cardiac arrhy-
thmias caused by microapplication of carbachol on the 
cortical structures of the rat’s brain
Injection of 29.3 μM of the SS-68 solution (marked by 
arrows in the Figure) suppresses epileptiform potentials 
induced by preliminary application of carbachol a few se-
conds after the artifact of the test substance microapplica-
tion. However, after a 10-minute observation, the epilepti-
form commissures adhesions are restored, which indicates 
a longer action of CCh than SS-68 compound (Fig. 19).
Figure 16. Comparative activity [according to ED50 in mg/kg 
(shaded bars) and mM/kg (dark bars)], relative activity (RA), 
acute toxicity (LD50) and therapeutic window (TW) SS-68, et-
mozine (Etm), ethacizine (Eth), anaprilin (An), lidocaine (Li) 
and amiodarone (Am) used to arrest aconitine-induced arrhyth-
mia of the central origin in experiments in anesthetized cats. 
Note: ED50 – effective dose; LD50 – dose that causes the death of 
50% of animals; RA –relative activity; TW - therapeutic window
Figure 17. Comparative activity [according to ED50 in mg/kg 
(shaded bars) and mM/kg (dark bars)], relative activity (RA), 
acute toxicity (LD50) and therapeutic window (TW) of SS-68, 
lidocaine (Li), etmozine (Etm), ethacizine (Eth), anaprilin (An), 
verapamil (Ve) and amiodarone (Am) used to treat strophan-
tine-induced arrhythmia of the central origin in experiments in 
anesthetized cats. Note: ED50 – effective dose; LD50 – dose that 
causes the death of 50% of animals; RA – relative activity; TW 
– therapeutic window
Figure 18. Comparative activity [according to ED50 in mg/kg 
(shaded bars) and mM/kg (dark bars)], relative activity (RA), 
acute toxicity (LD50) and therapeutic window (TW) of SS-68 
and amiodarone (Am) used to arrest cesium chloride- induced 
arrhythmia of central origin in experiments in anesthetized cats. 
Note: ED50 – effective dose; LD50 – dose that causes the death of 
50% of animals; RA – relative activity; TW - therapeutic win-
dow
Figure 19. Oppressive effect of SS-68 compound (29.3 μM) on 
the epileptiform activity caused by the preliminary exposure to 
CCh (12.5 mM). Note: K1 and K2 – the upper (400 μm immer-
sion depth) and the lower (1200 μm) layers of the cortex column, 
respectively, in which the microapplication of SS-68 was made. 
(up to 1 μl). The arrows mark the time of administration of SS-68.
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In conditions of HRD induced by the application of 
CCh to the cortical structures of the brain of animals, 
SS-68 has a pronounced antiarrhythmic effect (Fig. 20), 
which is confirmed by the previously obtained data on the 
ability of this substance to stop the central HRD induced 
by the introduction of aconitine, strophanthine and cesi-
um chloride into the IV ventricle of the cat’s brain.
The effect of SS-68 on coronary circulation, contractile 
activity of the myocardium and general hemodynami-
cs in conditions of intact myocardium
In experiments on cats in conditions of intact myocardi-
um, SS-68 (2 mg/kg, intravenously) increases CAFV, re-
duces MOD and creates the oxygen reserve (OR) in the 
myocardium, reduces the rhythm of heartbeats, slightly 
reduces the excitation propagation velocity in the heart, 
reduces myocardial contractility, and increases the refrac-
tory period (Fig. 21).
The influence on coronary blood flow in dogs
In experiments on dogs, SS-68, when administered intra-
coronarily (0.05 mg), increases both diastolic (at the end 
of diastole) and systolic coronary blood flow (Fig. 22). 
At the same time, the contractility of the myocardium is 
somewhat reduced (trend).
The influence of SS-68 compound on coronary cir-
culation, contractile myocardial activity and general 
hemodynamics in conditions of ischemic myocardium
The influence of SS-68 compound on the coronary arte-
ry flow velocity, cardiac activity and hemodynamics in 
ischemic myocardial conditions in dogs.
Figure 20. Antiarrhythmic effect of SS-68 in conditions of HRD 
induced by microapplication of CCh on the somatosensory cor-
tex of the rat’s brain. Note: K1 and K2 – the upper (400 μm 
immersion depth) and the lower (1200 μm) layers of the exper-
imental cortical column, respectively, in which the microappli-
cation was made (up to 1 μl) KX and the SS-68; K3 and K4 
– upper (400 microns) and lower (1500 microns) layers of the 
control column located at a distance of 1200 microns from the 
experimental one; K5 – the electrocardiogram.
Figure 21. Influence of SS-68 (2 mg/kg intravenously) on the 
blood supply of the heart in cats. Note: curves from top to bot-
tom: CAFV – coronary artery flow velocity, OR – oxygen re-
serve, BP – blood pressure, MOD – myocardial oxygen demand. 
* – significance in comparison with the initial data (p<0.05).
Figure 22. Influence of SS-68 (0.05 mg, intracoronarily) on the 
phasic coronary blood flow (PCBF) in dogs Note: Columns: 
1, 2 and 3 – peak of reactive hyperemia (RH) (% of the initial 
data), peak of the action of SS-68 (% of the initial data) and the 
expansion reserve (% of RH), respectively. CBFed – coronary 
blood flow (CBF) at end diastole; CBFds – CBF diastolic stroke; 
CBF min – diastolic CBF per minute; CBFb. – CBF per beat; BP 
– blood pressure; LVP – left ventricular pressure; PPCVed – per-
fusion pressure in the coronary vessels at end diastole; RCVed 
– resistance of coronary vessels at end diastole; CBFss – CBF 
systolic stroke; PPCVs – perfusion pressure in the coronary ves-
sels systolic; CBFI – CBF index; BPM – beats per minute (heart 
rate). * – the differences are statistically significant (p<0.05) 
compared to the baseline data.
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It was established that under conditions of ischemic myo-
cardial damage caused by occlusion of LAD, SS-68 (2 mg/
kg, intravenously) statistically significantly increased (com-
pared with the data received about prior and post-occlusi-
on of LAD) CAFV 15.5% and 26.0%, 54.2% and 68.1%, 
36.5% and 48.9%, 17.8% and 28.5% after 5, 10, 15, 30 and 
45 minutes, respectively. At the same time, MV, SV, BP, 
dp/dt+, dp/dt- and heart rate (compared with those after 10 
min of occlusion of LAD) showed a tendency to decrease. 
A certain exception was BP, which by the 45th minute of the 
study had decreased statistically significantly in compari-
son with the baseline data (before CAO) (Fig. 23, Fig. 24).
Thus, SS-68 compound, when administered intraven-
ously at a dose of 2 mg/kg in experiments in dogs, in-
creases collateral circulation in the myocardial ischemia 
focus, reduces myocardial oxygen demand, reduces blood 
pressure and heart rate (trend).
The influence on coronary circulation in conditions of 
myocardial ischemia induced by pituitrin in experiments 
in cats.
As a result of the conducted experiments, it was found 
that intravenous administration of pituitrin at a dose of 
5 units/kg to the control animals (n=9) induced (by the 
5th minute) in the majority of them a decrease in CAFV 
(by 25.6%, p<0.05) and a slight increase in BP (4.9%, 
p>0.05). At the same time, MOD increased slightly (by 
6.4%, p> 0.05), and OR decreased (by 30%, p<0.001). In 
322 other cats (n=4), on the contrary, there was an incre-
ase in CAFV (by 8-15%), along with an increase in MOD 
and BP (by 3.0-3.5 and 15-20%, respectively) (Fig. 25).
The influence of SS-68 compound on the functional state 
of the focus of myocardial ischemia in cats
It was established that preventive intravenous administra-
tion of SS-68 at a dose of 1 mg/kg increased the resistance 
of the myocardium to ischemia induced by occlusion of 
LAD, causing depression of ΣST in a most pronounced 
way (by 20.9%, 18.5%, 24.1%, 25.3% and 21.0%) 3 min 
after injection of the test substance (at the 0.5th, 1st, 2nd, 3rd 
and 4th minutes of CAO). The duration of the action was 
20 minutes (Fig. 26).
With increasing a dose of SS-68 to 2 mg/kg, the most 
significant ST-segment depression also occurred on the 3rd 
Figure 23. Influence of SS-68 (2 mg/kg, intravenously) on the 
coronary artery blood flow velocity (CAFV) in conditions of 
myocardial ischemia induced by occlusion of the coronary ar-
tery (CAO) in dogs.
Figure 24. Influence of SS-68 compound (2 mg/kg, intrave-
nously) on the blood supply of the myocardial ischemia focus 
in dogs. Note: VVRF – volume velocity of the retrograde blood 
flow; MOD (DP) – double product [index of myocardial oxygen 
demand (MOD)]; BP – blood pressure; OR – oxygen reserve; 
BPM – beats per minute (heart rate); * – the differences are sta-
tistically significant (p<0.05). 
Figure 25. Changes in indices in relation to the baseline data 5 
min after pituitrin-induced coronary spasm along with admin-
istration of SS-68 compound (2 mg/kg, intravenously) in cats. 
Note: CAFV – coronary artery blood flow velocity, MOD – 
myocardium oxygen demand, BP – blood pressure, OR – oxygen 
reserve. * – the differences are statistically significant (p<0.05).
Figure 26. Antianginal activity of SS-68 compound (1 mg/kg, 
intravenously) in experiments in cats. Note: * – the differences 
are statistically significant (p<0.05).
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minute after the administration of the substance and was 
34.3%, 40.5%, 39.2%, 35.2%, 33.8% and 29.2% at the 
0.5th, 1st, 2nd, 3rd, 4th and 5th min after CAO (Fig. 27). The 
duration of the action was 40 minutes.
The effect of SS-68 on the size of the necrotic zone (NZ) in 
experimental myocardial infarction in cats
It was found that with a double intravenous injection of 
SS-68 at a dose of 2 mg/kg (the total dose of 4 mg/kg) 
showed a statistically significant decrease in the necrotic 
zone (NZ) in experimental MI. While in the control series 
of experiments, the left ventricular NZ was 42.1%, in the 
experimental series – 21.2%, i.e., 49.6% less. When ana-
lyzing the protective effect of SS-68 by the levels of myo-
cardial sections, it turned out that the restriction of NZ is 
most significant at level I (62.1% less than in control), 
then at II, III, IV and V levels (by 55.4%, 46.5%, 35.0% 
and 19.8% less, respectively) (Fig. 28, Fig. 29).
Discussion
To date, there have been significant achievements of Rus-
sian and foreign pharmacologists, chemists and clinicians 
in creating and introducing into the practical medicine a 
number of antiarrhythmic drugs different by their chemi-
cal structure, nature, spectrum, activity and mechanism 
of action; nevertheless, one of the most important tasks 
of modern pharmacology is searching for and developing 
new highly active substances of the corresponding action 
(Kaverina 1986, Mashkovsky 1998, Yaroshevsky Gatsura 
2011, Galenko-Yaroshevsky et al. 2012a, 2012b, 2012c, 
2012d). This is due to the fact that HRDs often accompa-
ny many diseases: IHD and its complications (MI, acute 
and chronic HF), acquired and congenital heart defects, 
cardiomyopathies, myocarditis, exogenous intoxications 
and endogenous metabolic disorders in renal, hepatic and 
respiratory insufficiencies (Golitsyn 2008, Karpov and 
Sorokin 2012, Tiso et al. 2001).
In the present study, the antiarrhythmic and antianginal 
properties of a new indole derivative – SS-68 compound 
– were studied in detail. The models chosen cover a wide 
range of pathological conditions that can be extrapolated 
to most of the nosological forms found in clinical practice.
So, in cardiogenic arrhythmias, it was established that:
– under conditions of by aconitin-induced HRDs in ex-
periments in conscious rats, SS-68 by antiarrhythmic 
activity, with ED50 expressed in mg/kg, is comparable 
Figure 27. Antianginal effect of SS-68 comound (2 mg/kg, in-
travenously) in experiments in cats. Note: * – the differences are 
statistically significant (p<0.05).
Figure 28. Influence of a double intravenous administration of 
SS-68 compound at a dose of 2 mg/kg (the total dose of 4 mg/
kg) on the size of the necrotic zone (in %) 24 hours after the 
experimental myocardial infarction in cats. Note: A – control, 
B – after administration of SS-68. TA – total amount ; I, II, III, 
IV, V – levels of sections (blocks) of the heart.
Figure 29. Average mass of necrotic myocardium: in control (C) 
and under the influence of SS-68 compound (bar chart); total 
index of necrosis (in %) (pie chart, necrosis – darker sector).
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with lidocaine and is superior to amiodarone, and in 
experiments in anesthetized rats, SS-68 by antiarrhy-
thmic activity and TW is superior to lidocaine, amio-
darone, aymalin, and quinidine. The aconitine model of 
arrhythmia is associated with disruption of Na+ chan-
nels. Under the conditions of this model of arrhythmia, 
antiarrhythmic drugs belonging to the first class, which 
tend to block Na+-channels, have the most pronounced 
activity (Filippova et al. 2003, Galenko-Yaroshevsky 
et al. 2012c);
– in calcium chloride-induced arrhythmia model in ex-
periments in conscious rats, SS-68 (ED50 in mg/kg) 
by anti-arrhythmic activity is superior to lidocaine and 
amiodarone, but inferior to verapamil; it has a larger 
TW than reference drugs. In conditions of calcium 
chloride-induced arrhythmia, the effect of excess Ca2+ 
induces depolarization of cardiomyocytes, which leads 
to the appearance of ectopic foci of automatism and 
micro re-entry and, as a consequence, to the cardiac 
VF. In this model of arrhythmia, antiarrhythmics of the 
IV class and, to a lesser extent, of the I and II classes, 
show the greatest activity (Filippova et al. 2003, Ga-
lenko-Yaroshevsky et al. 2012с);
– in barium chloride-induced arrhythmia in experiments 
in conscious rabbits, SS-68 (ED50 in mg/kg) by anti-
arrhythmic activity and TW is superior to amiodarone 
and, to a greater extent, to quinidine. In this experi-
mental model, there is selective blockage of Ba2+ 
IK1-channels, prolongation of effective refractory peri-
od (ERP) of the ventricles of the heart, which leads to 
an increase in the level of Ca2+ in cardiomyocytes in 
AP, possibly, in RP (resting potential) (Filippova et al. 
2003, Dorian et al. 1996). In this HRD model, the most 
significant effect is exerted by blockers of K+-channels 
and β-adrenoblockers;
– when preventing cesium chloride-induced arrhythmia 
in experiments in anesthetized rats, SS-68, with ED50 
expressed in mg/kg, by its antiarrhythmic activity is 
superior to amiodarone. In cases of arresting cesium 
chloride-induced arrhythmia, SS-68, with ED50 ex-
pressed both in mg/kg and mM/kg, by its antiarrhyth-
mic activity is superior to amiodarone, but and does 
not differ from it in terms of TW. This model is charac-
terized by a disruption in the functioning of transmem-
brane potential-dependent K+-channels, and in this 
case, antiarrhythmic drugs of the third class are most 
effective (Galenko-Yaroshevsky et al. 2012с, Isenberg 
1976, Jones et al. 2001);
– in adrenaline-induced arrhythmia in experiments in 
anesthetized rats, SS-68 by its antiarrhythmic activity 
is superior to amiodarone (with ED50 expressed as in 
mg/kg) or comparable to it. This HRD model is specif-
ic for antiarrhythmics of classes II, and also IV (Filip-
pova et al. 2003, Galenko-Yaroshevsky et al. 2012c);
– in strophanthine-induced arrhythmia in experiments in 
anesthetized cats, SS-68 (with ED50 expressed in mg/
kg and mM/kg) by its antiarrhythmic activity is supe-
rior to lidocaine and quinidine, but inferior to aymalin 
and verapamil. In strophantine-induced arrhythmia, 
strophanthine increases the trigger activity of cardio-
myocytes, which causes the appearance of heterotro-
phic foci of excitation in the myocardium. In this HRD 
model, antiarrhythmics of classes I and II are most ef-
fective (Filippova et al. 2003, Galenko-Yaroshevsky et 
al. 2012c).
– in ventricular arrhythmia induced by a two-stage coro-
nary artery ligation in experiments in dogs, SS-68 has 
an antiarrhythmic effect, significantly exceeding lido-
caine. In ventricular arrhythmia induced by occlusion 
of LAD, antiarrhythmic effect is mainly exerted by the 
substances belonging to class I (Galenko-Yaroshevsky 
et al. 2012c).
– in paired stimulation of the atria in conditions of vagal 
blockade in cats, SS-68 eliminates AF. However, by 
antifibrillatory action in the experimental conditions, 
SS-68 is inferior to niferidil. In conditions of VF in-
duced by applying the electrostimulation to the vulner-
able period of the cardiac cycle, the drugs of classes I 
and III have an antiarrhythmic effect (Galenko-Yaro-
shevsky et al. 2012c).
– in conditions of ventricular HRD induced by experi-
mental MI (dogs), SS-68 compound by its the ability to 
completely stop ectopic contractions of ventricles and 
by the total duration of antiarrhythmic action exceeds 
lidocaine 5 times.
– in experiments on the isolated atrial appendage of the 
guinea pig’s heart,. SS-68 increases myocardial ERP, 
exceeding in this respect amiodarone, lidocaine and 
quinidine, but but being inferior to ethacizine.
In neurogenic HRD, we found that:
– in aconitine-induced arrhythmia in experiments in 
cats, SS-68 by its antiarrhythmic activity, with ED50 
expressed in mM/kg, exceeds amiodarone, lidocaine 
and etmozine and almost does not differ from anaprilin 
and ethacizine; but by TW, it is more significant than 
all the reference drugs;
– in strophanthine-induced arrhythmia in experiments in 
cats, SS-68 by its antiarrhythmic activity is superior to 
amiodarone, etmozine and lidocaine; however, it is in-
ferior to verapamil, anaprilin and ethacizine; by TW, it 
is more significant than anaprilin, ethacizine, etmozine 
and lidocaine, but is inferior to amiodarone and ver-
apamil;
– in cesium chloride-induced arrhythmia in experiments 
in cats, SS-68 by its antiarrhythmic activity is superior 
to amiodarone, but is inferior to it by TW;
– in carbachole-induced arrhythmia in experiments in 
rats, SS-68 exhibits a pronounced antiarrhythmic ef-
fect, exerts a depressing effect on the background focal 
rhythmogenesis of SSC of animals, suppresses the ep-
ileptiform activity of cortical structures.
Bogus SK et al.: 2-phenyl-1-(3-pyrrolidin-1-il-propyl)-1 H-indole hydrochloride (SS-68) ...148
When studying the antianginal properties and the effect 
on coronary blood flow, it was established that:
– under conditions of both intact (cats, dogs, rats) and 
ischemic (dogs) myocardium, SS-68 compound in-
creases the CAFV, creates additional OR in the myo-
cardium, reduces BP and, to a lesser extent, reduces 
myocardial contractility, and increases collateral circu-
lation in an ischemic focus;
– in pituitrin-induced coronarospasm (cats), SS-68 com-
pound increases CAFV, increases heart OR, reduc-
es MOD (trend) and blood pressure; SS-68 exerts an 
antianginal effect (rabbits, cats) and in this respect is 
comparable to amiodarone (by decreasing the ST in-
terval) or exceeds it (by the duration of action), but is 
inferior to anaprilin; it reduces myocardial NZ, sur-
passing amiodarone and, to a greater extent, anaprilin.
– with a double intravenous injection, SS-68 by its abil-
ity to limit NZ under conditions of experimental MI in 
cats is superior to or comparable to that of amiodarone 
and is more effective than anaprilin
Conclusions
Thus, SS-68 compound is a promising pharmacological 
agent with a high preventive and arresting effects towards 
various electrophysiological disorders in the heart, and, 
in addition, it has significant antiischemic and coronary 
vasolidating properties. Special attention should be paid 
to an in-depth study of the molecular mechanisms of acti-
on of this compound.
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